Surgical management for giant bladder leiomyosarcoma

Alexander A Hart; Charles H Schlaepfer; Neha Dhungana; Mohammed M Milhem; Vignesh T Packiam

doi:10.1016/j.eucr.2022.101995

Surgical management for giant bladder leiomyosarcoma

Urol Case Rep. 2022 Jan 7:42:101995. doi: 10.1016/j.eucr.2022.101995. eCollection 2022 May.

Authors

Alexander A Hart¹, Charles H Schlaepfer², Neha Dhungana³, Mohammed M Milhem⁴, Vignesh T Packiam²

Affiliations

¹ University of Iowa Carver College of Medicine, Iowa City, IA, USA.
² Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
³ Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
⁴ Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

Abstract

While urothelial carcinoma is the most common histologic type of bladder cancer in the United States, leiomyosarcoma is a rare and aggressive variant. The rarity of bladder leiomyosarcoma results in uncertainty regarding the optimal treatment pathway. We report on a patient with a giant non-metastatic bladder leiomyosarcoma effectively managed with primary surgical intervention without chemoradiation.

Keywords: Cystoprostoprostatectomy; Leiomyosarcoma; Oncology; Radical cystectomy; Urology.

Publication types

Case Reports

Grants and funding

P30 CA086862/CA/NCI NIH HHS/United States